Blood fat reducing traditional Chinese medicine composition as well as preparation method and application thereof

Through the combination of silylberry, epimedium, yuganzi and purple cypress extract, a traditional Chinese medicine composition for the treatment of hyperlipidemia was prepared, which solved the problem of excessive prescription of Chinese patent medicines and unclear efficacy, and achieved effective The effect of lowering blood lipids and repairing hepatocytes provides a safe and effective treatment plan.

CN119033839AInactive Publication Date: 2024-11-29FUWAI CENTRAL CHINA CARDIOVASCULAR HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411045942.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing Chinese patent medicines are prescribed too much for the treatment of hyperlipidemia, and the efficacy is unclear, and there are toxic side effects of chemical medicine treatment. Traditional Chinese medicine has fewer side effects in lowering blood lipids, but their effects are limited, making it difficult to promote.

Method used

Provide a traditional Chinese medicine composition for lowering blood lipids, including sily thistle, epimedium, yuganzi and purple cypress extract, which forms tablets, decoctions, powders or pills by decoction and extraction preparation method, for use in Prevent and treat hyperlipidemia, and prepare drugs in combination with pharmaceutical adjuvants.

Benefits of technology

This composition can not only effectively reduce cholesterol and triglyceride levels, repair damaged liver cells, protect liver cells from oxidative damage, thereby fundamentally treating hyperlipidemia, increasing high-density lipoprotein levels, and improving liver metabolism.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004974474160000091
    Figure BDA0004974474160000091
  • Figure BDA0004974474160000092
    Figure BDA0004974474160000092
  • Figure BDA0004974474160000111
    Figure BDA0004974474160000111
Patent Text Reader

Abstract

The embodiment of the invention discloses a blood fat reducing traditional Chinese medicine composition as well as a preparation method and application thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: 3-8 parts of silybum marianum; 4 to 10 parts of herba epimedii; 2 to 6 parts of emblic leafflower fruit; and 14-18 parts of a begonia fimbristipula extract. The traditional Chinese medicine composition disclosed by the embodiment of the invention not only can achieve a better effect of reducing blood fat, but also can repair damaged hepatocytes, so that the hyperlipemia can be fundamentally treated.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of traditional Chinese medicine, and in particular to a lipid-lowering traditional Chinese medicine composition, a preparation method thereof, and uses thereof. Background Art

[0002] Hyperlipidemia, also known as dyslipidemia, refers to one or more of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB) in plasma that are higher than normal, accompanied by a decrease in high-density lipoprotein cholesterol (HDL-C) and apolipoprotein AI (ApoAI). Hyperlipidemia can be caused by genetic and environmental factors, especially improper diet, and can also be induced by diabetes, obesity, pancreatitis, and liver, gallbladder, and kidney diseases.

[0003] Commonly used therapeutic drugs in clinical practice include chemical drugs and traditional Chinese medicine. Among them, chemical drugs generally have more toxic side effects. For example, commonly used statins, lipid-lowering drugs, may cause liver and kidney damage during use, or may cause muscle soreness, and in severe cases, may cause rhabdomyolysis. Traditional Chinese medicine not only has a relatively ideal result in lowering blood lipids, but also generally has no side effects or has relatively small side effects.

[0004] However, there are many Chinese patent medicines for treating hyperlipidemia, some of which have too many prescriptions (more than a dozen or even dozens of them), unclear efficacy, and are not conducive to promotion and application.

[0005] Therefore, the improvement of Chinese medicine for lowering blood lipids is an issue that needs to be urgently addressed. Summary of the invention

[0006] The purpose of the embodiments of the present application is to provide a lipid-lowering Chinese medicine composition and its preparation method and use.

[0007] To achieve the above technical objectives, the present application provides the following technical solutions:

[0008] In a first aspect, the present application provides a lipid-lowering Chinese medicine composition, which comprises, by weight:

[0009] Milk thistle: 3-8 servings;

[0010] Epimedium: 4-10 parts;

[0011] Phyllanthus emblica: 2-6 portions;

[0012] Gynura extract: 14-18 parts.

[0013] As an embodiment, the Chinese medicine composition further comprises:

[0014] Ligustrum lucidum: 4-8 servings.

[0015] As an embodiment, the weight ratio of the Gynura obesum extract to Silybum marianum is 2-4.25:1.

[0016] As an embodiment, the Chinese medicine composition comprises, by weight:

[0017] Milk thistle: 4-7 servings;

[0018] Epimedium: 5-8 parts;

[0019] Phyllanthus emblica: 2-5 portions;

[0020] Gynura extract: 14-16 parts;

[0021] Ligustrum lucidum: 5-8 servings.

[0022] As an embodiment, the preparation method of the Gynura extract comprises:

[0023] Take the crushed Gynura odoratum and soak it in 3-6 times the volume of ethanol for reflux extraction 2-5 times;

[0024] After cooling naturally to room temperature, the filtrates were combined;

[0025] The ethanol is removed by evaporation and concentrated to obtain an extract;

[0026] The extract is cooled and dried to obtain the Gynura extract.

[0027] As an embodiment, the ethanol is 70%-80% ethanol.

[0028] In a second aspect, the present application provides a method for preparing a lipid-lowering Chinese medicine composition as described in the first aspect, the preparation method comprising:

[0029] Weigh the raw materials according to the proportion, mix them evenly and then soak them in water to obtain soaked Chinese medicine;

[0030] The soaked Chinese medicine is boiled and filtered to obtain a filtrate;

[0031] The filtrate is cooled to obtain the Chinese medicine composition.

[0032] In a third aspect, the embodiments of the present application propose the use of the Chinese medicine composition as described in the first aspect in the preparation of a drug for preventing, alleviating or treating hyperlipidemia.

[0033] As an embodiment, the dosage form of the drug is tablets, decoctions, powders, pills or granules.

[0034] As an embodiment, the drug further comprises a pharmaceutically acceptable adjuvant.

[0035] The embodiments of the present application have at least the following beneficial effects:

[0036] The epimedium, emblica and gypsophila extracts used in this embodiment can not only reduce cholesterol content together with silymarin to achieve a better effect of lowering blood lipids; at the same time, silymarin can stimulate protein synthesis and normalize phospholipid metabolism in damaged liver cells, stabilize liver cell membranes, and emblica can promote the repair of liver cells (increase the level of high-density lipoprotein) in coordination with silymarin, and on the basis of repairing liver cells, epimedium and gypsophila extracts can also protect liver cells from oxidative damage together. Thus, the embodiment of the present application adopts the above-mentioned components, which can not only achieve a better effect of lowering blood lipids, but also repair damaged liver cells, so as to fundamentally treat hyperlipidemia.

[0037] Additional aspects and advantages of the present application will be partially given in the following description, which will become apparent from the following description, or will be understood through the practice of the present application. DETAILED DESCRIPTION

[0038] In order to more fully understand the technical content of the present application, the present application will be further introduced and illustrated in conjunction with specific embodiments below; obviously, the embodiments described below are only part of the embodiments of the present application, rather than all of the embodiments; based on the embodiments in the present application, all other embodiments obtained by those skilled in the art without making any creative work are within the scope of protection of the present application.

[0039] For those skilled in the art, the features, beneficial effects and advantages of the present application will become apparent by reading the contents disclosed in this specification.

[0040] The term "mass content" herein may be represented by the symbol "part(s)".

[0041] As used herein, "includes," "comprising," "including," "containing," "having," or other variations are intended to encompass non-closed inclusions, and no distinction is made between these terms. The term "comprising" means that other steps and ingredients that do not affect the end result may be added. The term "comprising" also includes the terms "consisting of" and "consisting essentially of." The compositions and methods / processes of the present application may include, consist of, and consist essentially of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, steps, or limitations described herein.

[0042] In the present application, the specific sources of Silybum marianum, Epimedium, Emblica officinalis, Gynura nigra and Ligustrum lucidum are not specifically limited. The above components can be purchased from the market or extracted or prepared by conventional methods known in the art.

[0043] For example, the purple back angelica extract in this embodiment was purchased from Lanzhou Waters Biotechnology Co., Ltd., or prepared by the preparation method provided in this embodiment. Epimedium and Ligustrum lucidum were purchased from Baoji Liupanyun Biotechnology Co., Ltd.; Phyllanthus emblica was purchased from Fufeng Snot Biotechnology Co., Ltd.; and Milk thistle was purchased from Shaanxi Yuanbeibei Biotechnology Co., Ltd., item number YBB-SFJ-6545.

[0044] The lipid-lowering Chinese medicine composition in the examples of the present application will be described in detail below.

[0045] Chinese medicine composition for lowering blood lipids

[0046] In the prior art, there are many Chinese patent medicines for treating hyperlipidemia, some of which have too large prescriptions, with as many as a dozen or even dozens of main ingredients, resulting in unclear efficacy and not conducive to promotion and application.

[0047] At present, in the selection of lipid-lowering drugs, the treatment principle is mainly focused on lowering blood lipids. However, the inventors of the present application believe that not only the effective lipid-lowering effect should be considered, but also how to repair damaged liver cells should be considered.

[0048] In view of this, this embodiment provides a lipid-lowering Chinese medicine composition, which includes, by weight: 3-8 parts of Silybum marianum; 4-10 parts of Epimedium; 2-6 parts of Phyllanthus emblica; and 14-18 parts of Gynura nigra extract.

[0049] Those skilled in the art know that silymarin in milk thistle can inhibit the activity of the rate-limiting enzyme in cholesterol synthesis, reduce cholesterol production, and thus exert the effect of lowering blood lipids; however, for patients with hyperlipidemia, the effect of using milk thistle alone is limited.

[0050] Based on this, this embodiment further adds epimedium, emblica and gynura extracts on the basis of milk thistle.

[0051] Among them, epimedium can not only reduce cholesterol content together with milk thistle, but also the polyphenol compounds contained in epimedium can scavenge free radicals and help protect liver cells from oxidative damage. The flavonoids and polysaccharides contained in emblica can reduce the cholesterol and triglyceride content in the body to achieve the effect of lowering blood lipids. Emblica can also work with milk thistle to increase the level of high-density lipoprotein in the blood, reduce liver damage and inflammation, promote and improve liver cell repair, and enhance the body's therapeutic effect on hyperlipidemia. The extract of purple-backed geranium contains flavonoid components that strengthen capillaries and reduce blood viscosity. It has the effect of inhibiting the formation of fatty liver and reducing serum fat. At the same time, purple-backed geranium also has the effect of protecting the liver.

[0052] Specifically, the extracts of epimedium, emblica and gynura strychnifolia used in this embodiment can not only reduce the cholesterol content together with silymarin to achieve a better lipid-lowering effect; at the same time, silymarin can stimulate protein synthesis and normalize phospholipid metabolism in damaged liver cells, stabilize liver cell membranes, and emblica can synergistically promote liver cell repair (increase the level of high-density lipoprotein) with silymarin. On the basis of repairing liver cells, epimedium and gynura strychnifolia extracts can also protect liver cells from oxidative damage together.

[0053] Therefore, the above components used in this embodiment can not only achieve a better effect of lowering blood lipids, but also repair damaged liver cells, thereby fundamentally treating hyperlipidemia.

[0054] It can be understood that the high-density lipoprotein described in this embodiment can combine with blood lipids in the body to remove cholesterol, thereby improving the body's condition; therefore, this embodiment can promote liver metabolism by increasing the level of high-density lipoprotein, thereby improving the body's overall therapeutic effect on hyperlipidemia.

[0055] The Gynura extract of this embodiment can be purchased from Lanzhou Waterless Biotechnology Co., Ltd.

[0056] It is understandable that the Gynura extract can also be prepared by existing known preparation methods.

[0057] For example, the preparation method of the extract of Gynura serrata comprises:

[0058] Take the crushed Gynura odoratum and soak it in 3-6 times the volume of ethanol for reflux extraction 2-5 times;

[0059] After cooling naturally to room temperature, the filtrates were combined;

[0060] The ethanol was removed by evaporation and the extract was obtained by concentration;

[0061] The extract is cooled and dried to obtain the Gynura serrata extract.

[0062] As an embodiment, the volume of ethanol can be 3-6 times that of Gynura odoratum, such as 3 times, 4 times, 5 times or 6 times, preferably 5 times; the number of reflux extractions can be 2-5 times, such as 3 times, 4 times, 5 times or 6 times, preferably 5 times; the ethanol is 70%-80% ethanol, such as 70% ethanol, 75% ethanol or 80% ethanol. Preferably, it is 75% ethanol.

[0063] Among them, Gynura odoratum was purchased from Bozhou Deng Dawei Pharmaceutical Co., Ltd.

[0064] As a more preferred embodiment, the preparation method of the Gynura extract comprises:

[0065] Take the crushed (100-150 mesh) Gynura odoratum, soak it in 5 times the volume of 75% ethanol and reflux extract it 3 times;

[0066] After cooling naturally to room temperature, the filtrates were combined;

[0067] Evaporate to remove ethanol at 75-79°C and concentrate to obtain an extract;

[0068] The extract is cooled and dried at room temperature, crushed and sieved (100-150 meshes) to obtain the Gynura serrata extract.

[0069] Among them, Gynura odoratum was purchased from Bozhou Deng Dawei Pharmaceutical Co., Ltd.

[0070] As a preferred technical solution of this embodiment, the Chinese medicine composition of this embodiment includes, by weight: 4-7 parts of Silybum marianum; 5-8 parts of Epimedium; 2-5 parts of Emblica officinalis; and 14-16 parts of Gynura ovata extract.

[0071] For example, in this embodiment:

[0072] The content of milk thistle includes but is not limited to: 3 parts, 4 parts, 4.5 parts, 4.9 parts, 5 parts, 5.3 parts, 5.5 parts, 5.7 parts, 6 parts, 6.2 parts, 6.4 parts, 7 parts, 7.7 parts, 7.9 parts, and 8 parts.

[0073] The content of Epimedium includes but is not limited to: 4 parts, 4.5 parts, 4.9 parts, 5 parts, 5.5 parts, 5.6 parts, 7 parts, 7.5 parts, 7.8 parts, 8 parts, 8.4 parts, 9 parts, 9.5 parts, 9.6 parts, and 10 parts.

[0074] The content of emblica emblica includes but is not limited to: 2 parts, 3 parts, 4 parts, 5 parts, and 6 parts.

[0075] The contents of the extract of Gynura ovata include but are not limited to: 14 parts, 14.2 parts, 14.5 parts, 14.6 parts, 14.7 parts, 15 parts, 15.2 parts, 15.4 parts, 15.6 parts, 15.7 parts, 15.9 parts, 16 parts, 16.4 parts, 16.5 parts, 16.9 parts, 17 parts, 17.5 parts, 17.8 parts, and 18 parts.

[0076] As the preferred technical solution of this embodiment, the weight ratio of the extract of Gynura serrata to Silybum marianum is 2-4.25:1, more preferably 2:1; this embodiment confirms through relevant experiments that within this range, the Chinese medicine composition of the present application has a better lipid-lowering effect.

[0077] Ligustrum lucidum

[0078] In addition to the above components, the Chinese medicine composition of this embodiment, as a preferred implementation of this embodiment, also includes: Ligustrum lucidum: 4-8 parts.

[0079] Among them, the inventors have found through verification that further adding Ligustrum lucidum to the above-mentioned traditional Chinese medicine composition can better achieve the effect of lowering blood lipids and further repair damaged liver cells. It is speculated that the principle may be:

[0080] Ligustrum lucidum can effectively lower the low-density lipoprotein (bad cholesterol) in the blood, while increasing the level of high-density lipoprotein (good cholesterol); therefore, Ligustrum lucidum can work with Epimedium and Gynura asiatica extracts to lower blood lipids, and can also synergize with Milk thistle and Emblica officinalis to increase high-density lipoprotein in the blood to promote and improve the repair of liver cells.

[0081] In this embodiment:

[0082] The content of Ligustrum lucidum includes but is not limited to: 4 parts, 4.5 parts, 4.9 parts, 5 parts, 5.3 parts, 5.5 parts, 5.7 parts, 6 parts, 6.2 parts, 6.4 parts, 7 parts, 7.7 parts, 7.9 parts, and 8 parts.

[0083] Preparation method

[0084] The preparation method of the above-mentioned lipid-lowering Chinese medicine composition will be described in detail below. The preparation method comprises:

[0085] Weigh the raw materials according to the proportion, mix them evenly and then soak them in water to obtain soaked Chinese medicine;

[0086] The soaked Chinese medicine is boiled and filtered to obtain a filtrate;

[0087] The filtrate is cooled to obtain the Chinese medicine composition.

[0088] Among them, the amount of water added is usually based on 4-8 cm of the Chinese medicine composition, preferably 5 or 6 cm; the soaking time is usually 1-2 hours, preferably 1 hour; the decoction temperature is 90-100°C, preferably 95°C; the decoction time is 1-3 hours, preferably 1.5 hours; the above-mentioned cooling refers to cooling at room temperature to a temperature that can be taken orally or by gavage.

[0089] The temperature for oral administration is 30-40℃, and the temperature for intragastric administration is 32-38℃.

[0090] Hyperlipidemia drugs

[0091] Since the Chinese medicine composition of this embodiment can effectively reduce blood lipids and repair damaged liver cells, the Chinese medicine composition provided in this embodiment can be used to prepare a drug for preventing, alleviating or treating hyperlipidemia.

[0092] That is, the Chinese medicine composition of this embodiment can be used as a basis, and pharmaceutically acceptable adjuvants can be added to prepare a drug for treating hyperlipidemia.

[0093] Exemplarily, the dosage form of the hyperlipidemia drug is tablets, decoctions, powders, pills or granules.

[0094] Adjuvants

[0095] It should be understood that the pharmaceutically acceptable excipient used in this embodiment refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the Chinese medicine composition formulated together.

[0096] Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the composition of the present invention include (but are not limited to) wetting agents, binders or disintegrants. The types and amounts of the above-mentioned wetting agents, binders or disintegrants should comply with the relevant provisions of the Chinese Pharmacopoeia.

[0097] For example, the disintegrant can be selected from one or more of sodium carboxymethylcellulose CMC, CMC-Na, and HPM.

[0098] It should be understood that the above-mentioned adjuvants may be selected in combination with the specific dosage form of the drug.

[0099] Drug administration

[0100] The drugs provided in this embodiment can be administered by many routes, including but not limited to: oral administration, parenteral administration, inhalation administration, topical administration or other modes of administration. For example, the drugs used herein are drugs for oral administration or injectable solutions.

[0101] The present application is further described below in conjunction with the examples. It should be understood that these examples are only used to illustrate the present application and are not used to limit the scope of the present application.

[0102] In the following examples, the materials, reagents and instruments used can be purchased from commercial sources unless otherwise specified.

[0103] In the following examples and comparative examples, the Gynura extract was prepared by the following preparation method:

[0104] Take the crushed (100 mesh) Gynura serrata, soak it in 5 times the volume of 75% ethanol and reflux extract it 3 times;

[0105] After cooling naturally to room temperature, the filtrates were combined;

[0106] Evaporate to remove ethanol at 77-79°C and concentrate to obtain an extract;

[0107] The extract is cooled and dried at room temperature, crushed and sieved (100 meshes) to obtain the Gynura serrata extract.

[0108] Examples 1-7

[0109] Examples 1-7 respectively provide Chinese medicine compositions with the components shown in Table 1, and each component in the Chinese medicine composition is measured by weight.

[0110] Table 1: Composition of the Chinese medicine composition of Examples 1-7 (parts)

[0111]

[0112] Comparative Example 1-Comparative Example 4

[0113] Comparative Examples 1-4 respectively provide Chinese medicine compositions with the components shown in Table 2, and each component in the Chinese medicine composition is measured by weight.

[0114] Table 2: Composition of the Chinese medicine composition of Comparative Examples 1-4 (parts)

[0115]

[0116] The preparation method of the Chinese medicine composition of Examples 1-7 and Comparative Examples 1-4 comprises the following steps:

[0117] Weigh each raw material according to the proportion, mix them evenly, then add water and soak for 1 hour to obtain soaked Chinese medicine;

[0118] The soaked Chinese medicine was boiled at 95°C for 1.5 hours and then filtered to obtain a filtrate;

[0119] The filtrate is cooled at room temperature to obtain the corresponding Chinese medicine composition (decoction);

[0120] The amount of water added is to cover the Chinese medicine composition by 5 cm.

[0121] Effect verification

[0122] The Chinese medicine composition prepared above was tested for reducing blood lipids.

[0123] Lipid-lowering test

[0124] Materials and Methods

[0125] 1.1 Materials

[0126] The experimental animals were Wister rats, weighing 160-180 g, half male and half female, 104 rats.

[0127] 1.2 Grouping and Methods

[0128] 104 rats were divided into 13 groups, and after one week of adaptive feeding in the animal room, they were divided into a normal group (8 rats) and an experimental group (96 rats);

[0129] The normal group was fed with ordinary feed, while the experimental group was fed with high-fat feed;

[0130] The composition of ordinary feed is: 25% flour, 20% cornmeal, 15% sorghum flour, 20% bean cake, 10% wheat bran, 7% fish meal, 2% bone meal, 1% salt. The composition of high-fat feed is: 65% of the above ordinary feed, 16% lard, 9% cholesterol, and 10% sucrose.

[0131] The rats in each group were allowed to drink water and eat freely; after 4 weeks of feeding, the body weight was measured and the experimental group was made into a high-fat model group. 96 rats in the high-fat model group were randomly divided into 12 groups, including the high-fat model group, Example 1-7 groups and Comparative Example 1-4 groups, with 8 rats in each group.

[0132] Intragastric administration:

[0133] The groups of Examples 1-7 and Comparative Examples 1-4 were given the Chinese medicine compositions prepared in the corresponding groups, and the dosage was calculated based on the raw medicine amount of 10 g / kg; the high-fat model group and the normal group were given the same dose of normal saline. After continuous intragastric administration for 4 weeks, the subjects were fasted but not watered for 12 hours; the serum was taken and the levels of total cholesterol (TC), total triglycerides (TG), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C) in the serum were determined using an automatic biochemical analyzer.

[0134] The experimental data were statistically processed using SPSS13.0 software, and the index values ​​were expressed as mean ± standard deviation. The t test was used for comparison between groups. The test results are shown in Table 3.

[0135] Table 3: Results of lipid-lowering test

[0136]

[0137] Note: In the above table, * indicates that the comparison with the normal group is statistically significant, *P < 0.05; # indicates that the comparison with the high-fat model group is statistically significant, #P < 0.05; △ indicates that the comparison with the Example 3 group is statistically significant, △P < 0.05.

[0138] According to the test results in Table 3, by comparing the high-fat model group with the normal group, it can be seen that after the model rats were fed with high-fat for 4 weeks, their blood lipid index was significantly higher than that of the normal group, with significant statistical differences (*P<0.05), indicating that the model was successfully established.

[0139] Among them, Examples 1-4 used extracts of milk thistle, epimedium, emblica and gynura ovata, and the levels of total cholesterol, total triglycerides and low-density lipoprotein in rats decreased significantly, and the level of high-density lipoprotein increased significantly, indicating that the Chinese medicine composition of Examples 1-4 can effectively regulate blood lipid metabolism in patients with hyperlipidemia.

[0140] Specifically, Example 5-7 further adds Ligustrum lucidum to Example 3. Compared with Example 3, the levels of total cholesterol, total triglycerides and low-density lipoprotein in the rats of Example 5-7 are significantly decreased, and the level of high-density lipoprotein is significantly increased; this indicates that Ligustrum lucidum in this example can effectively reduce low-density lipoprotein (bad cholesterol) in the blood, while increasing the level of high-density lipoprotein (good cholesterol); therefore, Ligustrum lucidum can lower blood lipids together with Epimedium and Gynura asiatica extracts, and can also synergistically increase blood high-density lipoprotein with Emblica officinalis, so as to promote and improve the repair of liver cells.

[0141] It is particularly important to emphasize that the Fructus Ligustri Lucidi of the present embodiment can cooperate with Fructus Emblicae and Silybum Marianum to better increase high-density lipoprotein in the blood, thereby promoting liver metabolism and further improving the body's overall therapeutic effect on hyperlipidemia.

[0142] Further comparing Example 3 with Comparative Examples 1-2, compared with Example 3, when Comparative Examples 1-2 lacked one of milk thistle or epimedium, the levels of total cholesterol, total triglycerides and low-density lipoprotein in rats increased significantly (the lipid-lowering effect decreased), and the high-density lipoprotein level decreased significantly. This shows that in the scheme of this embodiment, milk thistle or epimedium can work together to reduce cholesterol content to achieve a better lipid-lowering effect; among them, according to the test results of Comparative Example 1, milk thistle can significantly increase the expression level of high-density lipoprotein in this embodiment to promote and improve the repair of liver cells.

[0143] Further comparing Example 3 and Comparative Examples 3-4, compared with Example 3, when Comparative Examples 3-4 lacked one of the extracts of Phyllanthus emblica or Gynura australis, the levels of total cholesterol, total triglycerides and low-density lipoprotein in rats also increased significantly (the lipid-lowering effect decreased), and the high-density lipoprotein level decreased significantly. This shows that the extracts of Milk Thistle, Epimedium, Phyllanthus emblica and Gynura australis in this embodiment can not only work together to better reduce blood lipids, but also repair damaged liver cells, thereby fundamentally treating hyperlipidemia.

[0144] Among them, the decrease in high-density lipoprotein levels in Comparative Example 1 (lack of milk thistle) and Comparative Example 3 (lack of emblica fruit) was more obvious, indicating that milk thistle and emblica fruit in the composition of this embodiment can better affect the expression level of high-density lipoprotein, thereby affecting the overall lipid-lowering effect of the traditional Chinese medicine composition.

[0145] Specifically, Example 3 can promote liver metabolism by significantly increasing the level of high-density lipoprotein, thereby improving the body's overall therapeutic effect on hyperlipidemia; therefore, the lipid-lowering effects of Example 3 and Examples 5-7 are more significant.

[0146] In summary, the Herba Epimedii, Fructus Phyllanthus and Gynura strychnifolia extracts used in this embodiment can not only reduce cholesterol content together with Milk Thistle to achieve a better effect of lowering blood lipids; at the same time, Silymarin can stimulate protein synthesis and normalize phospholipid metabolism in damaged liver cells, stabilize liver cell membranes, Fructus Phyllanthus and Silymarin can promote the repair of liver cells (increase the level of high-density lipoprotein) in a coordinated manner, and on the basis of repairing liver cells, Herba Epimedii and Gynura strychnifolia extracts can also protect liver cells from oxidative damage together. Thus, this embodiment uses the above components, which can not only achieve a better effect of lowering blood lipids, but also repair damaged liver cells, thereby fundamentally treating hyperlipidemia.

[0147] At the same time, Ligustrum lucidum can effectively lower the low-density lipoprotein (bad cholesterol) in the blood, while increasing the level of high-density lipoprotein (good cholesterol); therefore, Ligustrum lucidum can work with Epimedium and Gynura asiatica extracts to lower blood lipids, and can also synergize with Emblica officinalis to increase high-density lipoprotein in the blood to promote and improve the repair of liver cells, thereby better treating hyperlipidemia.

[0148] It is worth noting that the Chinese medicine composition and the hyperlipidemia drug described in this embodiment may be subject to changes in the formulation system and administration method during specific use.

[0149] The technical solutions provided in the embodiments of the present application are introduced in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the embodiments of the present application. The description of the above embodiments is only applicable to help understand the principles of the embodiments of the present application. At the same time, for those skilled in the art, according to the embodiments of the present application, there will be changes in the specific implementation methods and application scopes. In summary, the contents of this specification should not be understood as limiting the present application.

Claims

1. A Chinese medicine composition for lowering blood lipids, characterized in that: The Chinese medicine composition comprises, by weight: Milk thistle: 3-8 servings; Epimedium: 4-10 parts; Phyllanthus emblica: 2-6 servings; Gynura serrata extract: 14-18 parts.

2. The blood lipid lowering Chinese medicine composition according to claim 1, characterized in that The Chinese medicine composition further comprises: Ligustrum lucidum fruit: 4-8 servings.

3. The blood lipid lowering Chinese medicine composition according to claim 2, characterized in that The weight ratio of the Gynura serrata extract to milk thistle is 2-4.25:

1.

4. The lipid-lowering Chinese medicine composition according to claim 2 or 3, characterized in that The Chinese medicine composition comprises, by weight: Milk thistle: 4-7 servings; Epimedium: 5-8 parts; Emblic: 2-5 servings; Gynura serrata extract: 14-16 parts; Ligustrum lucidum: 5-8 servings.

5. The blood lipid lowering Chinese medicine composition according to claim 1, characterized in that The preparation method of the Gynura serrata extract comprises: Take the crushed Gynura odorata and soak it in 3-6 times the volume of ethanol and reflux extract it 2-5 times; After cooling naturally to room temperature, the filtrates were combined; Evaporation removes ethanol and concentration obtains the extract; The extract is cooled and dried to obtain the Gynura serrata extract.

6. The blood lipid lowering Chinese medicine composition according to claim 5, characterized in that The ethanol is 70%-80% ethanol.

7. A method for preparing the lipid-lowering Chinese medicine composition according to any one of claims 1 to 6, characterized in that: The preparation method comprises: Weigh the raw materials in proportion, mix them evenly, and then soak them in water to obtain soaked Chinese medicine; The soaked Chinese medicine is boiled and filtered to obtain a filtrate; The filtrate is cooled to obtain the Chinese medicine composition.

8. Use of the traditional Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for preventing, alleviating or treating hyperlipidemia.

9. The use according to claim 8, characterized in that The dosage form of the medicine is tablet, decoction, powder, pill or granule.

10. The use according to claim 8 or 9, characterized in that The medicament further includes pharmaceutically acceptable adjuvants.